KR20110085433A - Composition for relieving hangover containing bulnesia sarmienti extracts - Google Patents
Composition for relieving hangover containing bulnesia sarmienti extracts Download PDFInfo
- Publication number
- KR20110085433A KR20110085433A KR1020100005218A KR20100005218A KR20110085433A KR 20110085433 A KR20110085433 A KR 20110085433A KR 1020100005218 A KR1020100005218 A KR 1020100005218A KR 20100005218 A KR20100005218 A KR 20100005218A KR 20110085433 A KR20110085433 A KR 20110085433A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- alcohol
- group
- blancia
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 62
- 206010019133 Hangover Diseases 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 235000009579 balsamo Nutrition 0.000 title claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 49
- 239000008280 blood Substances 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008196 pharmacological composition Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 239000000843 powder Substances 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 4
- 239000000839 emulsion Substances 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 4
- 239000000725 suspension Substances 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 abstract description 4
- 239000000829 suppository Substances 0.000 abstract description 3
- 239000006188 syrup Substances 0.000 abstract description 3
- 235000020357 syrup Nutrition 0.000 abstract description 3
- 239000000443 aerosol Substances 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract description 2
- 235000019441 ethanol Nutrition 0.000 description 51
- 235000013361 beverage Nutrition 0.000 description 24
- 230000000694 effects Effects 0.000 description 18
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 13
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229960003726 vasopressin Drugs 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 3
- 108010004977 Vasopressins Proteins 0.000 description 3
- 102000002852 Vasopressins Human genes 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- -1 licorice extract Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000935112 Bulnesia Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000020737 peppermint extract Nutrition 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229930182496 polymethoxyflavone Natural products 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 블렌시아 살미언티 추출물 함유 숙취해소용 조성물에 관한 것으로, 보다 구체적으로는 블렌시아 살미언티 추출물을 함유하여 혈액 내 알코올 농도와 아세트알데히드 농도를 감소시키는 숙취해소용 조성물에 관한 것이다.
The present invention relates to a composition for releasing hangover, containing blancia salmity extract, and more particularly, to a composition for releasing hangover, which contains blancia salmity extract and reduces alcohol concentration and acetaldehyde concentration in blood.
음주 후 나타나는 숙취는 에탄올 자체로도 독성을 나타낼 수 있을 뿐 아니라 체내에서 대사과정 중 인체에 해로운 물질로 전환될 수 있고, 이것은 뇌와 간을 포함한 소화기관에 유해한 물질로 작용하므로 인해 나타나는 현상이다. 알코올은 다른 식품과 달리 조직 내에 저장되지 못하고 알코올 탈수소효소(alcohol dehydrogenase; ADH)의 촉매 작용에 의해 아세트알데히드로 산화되며, 다시 알데히드탈수소효소(aldehyde dehydrogenase; ALDH)의 촉매작용으로 아세트산과 수소로 된다. 형성된 아세트산의 90%는 직접 CO2와 H2O가 되며 약 10%는 TCA 사이클을 거쳐서 완전히 분해된다. The hangover that appears after drinking alcohol is not only toxic but also can be converted into harmful substances in the body during metabolism, which is caused by harmful substances in the digestive system including brain and liver. Unlike other foods, alcohol is not stored in tissues and is oxidized to acetaldehyde by the catalytic action of alcohol dehydrogenase (ADH), and then to acetic acid and hydrogen by the catalytic action of aldehyde dehydrogenase (ALDH). . 90% of the acetic acid formed is directly CO 2 and H 2 O and about 10% is completely decomposed through the TCA cycle.
숙취의 원인물질로 알려진 아세트알데히드는 간의 마이크로좀에서 시스테인과 글루타티온을 비롯한 함유 황물질과 높은 친화력을 가지고, 혈장막의 지질분 변화를 유발하여 지방간 및 간괴사 등의 간 손상을 일으킨다. 알코올은 섭취량에 따라 신체에 여러 가지 영향을 미치는데 짧은 시간 내에 과량의 알코올 섭취는 알데히드의 축적과 함께 구토, 두통, 혈압저하, 빈맥 및 쇼크 등을 유발하고, 특히 간 내 지질 산화나 소포체에서의 약물대사 등을 방해하며, 만성적인 섭취에는 적응성이 유도되어 알코올 및 약물의 대사가 증가하고 지단백질의 생성이 가속화됨으로써 간세포의 손상을 가져온다. 이러한 유해현상은 아세트알데히드의 생성시에 발생하는 과산화 반응과 MEOS의 촉매에 의해 형성된 과량의 NADH에 의한 간세포의 파괴, 간세포의 화학적평형저해, 대사이상 및 미토콘드리아의 기능 저해에서 기인된다Acetaldehyde, known as a causative agent of hangover, has a high affinity with sulfur-containing substances, including cysteine and glutathione, in the liver microsomes, causing lipid changes in the plasma membrane and causing liver damage such as fatty liver and liver necrosis. Alcohol affects the body depending on the amount of intake.In a short time, excessive alcohol intake causes vomiting, headache, lowering blood pressure, tachycardia and shock along with accumulation of aldehyde, especially in liver lipid oxidation or endoplasmic reticulum. Interfering with drug metabolism, chronic intake, adaptability is induced to increase the metabolism of alcohol and drugs and accelerate the production of lipoproteins, resulting in damage to liver cells. These harmful phenomena are due to the peroxidation reactions that occur during the production of acetaldehyde and the destruction of hepatocytes by excess NADH formed by the catalyst of MEOS, impaired chemical equilibrium of hepatocytes, metabolic abnormalities and impaired mitochondrial function.
이 같은 유해반응 및 유해물질은 간세포의 손상을 초래하여 젖산과 같은 피로물질의 축적을 유도하며 ALDH의 활성을 감소시키고 비타민의 활성화를 저해하여 혈중 비타민의 양을 감소시키고 심장의 근육단백질 합성도 억제한다. 더욱이 증가된 수소는 직접 또는 간접적으로 지방산의 합성에 관여하여 지방질 등을 형성함으로써 지방간이라는 병리적 현상을 초래한다.These harmful reactions and harmful substances cause hepatic cell damage, leading to the accumulation of fatigue substances such as lactic acid, reducing the activity of ALDH, inhibiting the activation of vitamins, reducing the amount of vitamins in the blood and inhibiting the synthesis of muscle protein in the heart. do. Furthermore, the increased hydrogen is directly or indirectly involved in the synthesis of fatty acids to form fat and the like, resulting in a pathological phenomenon called fatty liver.
이와 같은 숙취로 인한 문제점을 해소하기 위하여 다양한 숙취해소용 물질들이 제안된 바 있다. 예를 들어, 폴리메톡시플라본 계열의 화합물을 유효성분으로 포함하는 숙취 해소용 조성물(대한민국 등록특허 제10-0912243호), 오르니친을 포함하는 것을 특징으로 하는 숙취해소용 조성물 또는 알코올 음료(대한민국 등록특허 제10-0903690호), 죽초액, 감초 추출물, 허브 추출물, 대추 추출물, 페퍼민트 추출물 및 홍삼 추출물을 유효성분으로 포함하여 숙취해소, 간장보호 및 피로회복에 효과가 있는 음료 조성물(대한민국 등록특허 제10-0913243호), 감잎 추출물을 주성분으로 함유하는 숙취해소용 조성물(대한민국 등록특허 제10-0877507호), 고추잎 추출물을 주성분으로 하여 여러 가지 한약재를 첨가한 숙취해소용 조성물(대한민국 등록특허 제10-0853939호) 등이 개발되었다.
In order to solve the problems caused by hangovers, various hangover-reducing substances have been proposed. For example, a hangover relief composition (Korean Patent No. 10-0912243) comprising a polymethoxyflavone-based compound as an active ingredient, a hangover relief composition or an alcoholic beverage (Korea) Patent No. 10-0903690), a beverage composition effective in relieving hangovers, protecting the liver and recovering fatigue, including bamboo vinegar, licorice extract, herbal extract, jujube extract, peppermint extract, and red ginseng extract as active ingredients. 10-0913243), hangover releasing composition containing persimmon leaf extract as a main ingredient (Korean Patent No. 10-0877507), hangover releasing composition added various herbal medicines using pepper leaf extract as a main ingredient (Korea Registered Patent No. 10-0853939).
블렌시아 살미언티(Bulnesia sarmienti)는 아메리카 대륙의 깊은 오지에서 야생 형태로만 자생하며 원주민(Native 인디언)들에 의해 신비의 약초라고 하여 질병치유에 많이 이용되어 왔다. 현재 블렌시아 살미언티에서 추출된 구아이악우드 오일(guaiacwood oil)이 미국에서 상품화되어 향기 등으로 판매되고 있으며, 이는 LD50가 5000mg/kg 이상으로 독성이 거의 없는 것으로 확인되었다. Bulnesia sarmienti grows wild only in the deep outcrops of the Americas and has been widely used by the Native Indians as a mysterious herb for healing diseases. Currently, guiacwood oil extracted from Blensia Salmonti is commercialized in the United States and sold as fragrance, and it is confirmed that LD50 is more than 5000 mg / kg and is almost non-toxic.
최근 들어 이러한 블렌시아 살미언티 추출물의 항산화 및 항암효과가 밝혀진바 있으며, 체지방감소효과, 혈중지질개선효과 및 혈행개선 효과가 있음 또한 밝혀진 바 있다. Recently, the antioxidant and anticancer effects of the Blencia salmianti extract have been found, and it has also been found that there is a body fat reduction effect, blood lipid improvement effect and blood circulation improvement effect.
블렌시아 살미언티와 관련하여, 대한민국 등록특허 제10-0890945호 “블렌시아 살미언티 추출물을 함유하는 음료 및 그 제조방법”에 최적조건에서 추출하여 얻은 블렌시아 살미언티 추출물과 이를 유효성분을 포함하는 음료의 제조 방법이 개시되어 있으며, 대한민국 특허출원 제10-2008-0014334호 “혈중 지질개선, 체지방감소 또는 혈행개선 효과를 갖는 블렌시아 살미언티 추출물”에 블렌시아 살미언티(Bulnesia sarmienti)의 추출물 및 이에 단삼 또는 상백피를 단독 또는 복합 추가한 혼합추출물이 체지방감소, 혈중지질개선 또는 혈행개선 효과가 있음이 개시되어 있다. 하지만 아직까지 블렌시아 살미언티 추출물의 숙취해소 효과에 대해서는 보고된 바 없다.With respect to blancia salmianti, blancia salmianti extract obtained by extracting at optimal conditions in Korean Patent No. 10-0890945 "Beverage containing blancia salmianti extract and its manufacturing method" and the active ingredient A method for preparing a beverage containing the same is disclosed, and Korean Patent Application No. 10-2008-0014334 "Blensia Salmonity Extract having a blood lipid improvement, body fat reduction or blood circulation improvement effect" in the Blensia Salmonti (Bulnesia) sarmienti extracts and mixed extracts added alone or in combination with Salvia Miltiorrhiza (P. ginseng or Lepidoptera) have been shown to reduce body fat, improve blood lipids, or improve blood circulation. However, there has been no report on the hangover effect of the Blensia salmity extract.
이에 본 발명자들은 숙취해소에 효과적인 물질을 탐색하고, 이를 이용한 숙취해소용 조성물을 제조하기 위해 예의 연구를 거듭한 결과 블렌시아 살미언티 추출물이 숙취해소에 효과적임을 확인하고 본 발명에 이르게 되었다.
Accordingly, the present inventors searched for an effective substance for releasing hangovers, and conducted intensive studies to prepare a hangover releasing composition using the same.
따라서 본 발명의 목적은 블렌시아 살미언티(Bulnesia sarmienti) 추출물을 유효성분으로 함유하는 숙취해소용 약제학 조성물을 제공하는 것이다.Therefore, an object of the present invention is to provide a hangover relief pharmaceutical composition containing Bulnesia sarmienti extract as an active ingredient.
또한 본 발명의 다른 목적은 블렌시아 살미언티(Bulnesia sarmienti) 추출물을 유효성분으로 함유하는 숙취해소용 식품 조성물을 제공하는 것이다.
In addition, another object of the present invention to provide a hangover relief food composition containing Bulnesia sarmienti extract as an active ingredient.
상기와 같은 본 발명의 목적은 블렌시아 살미언티 추출물을 제조하고, 이의 혈액 중 알코올 농도, 알콜탈수소효소(ADH) 및 아세트알데히드(ALDH) 농도에 미치는 영향을 무처치 정상군, 에탄올 대조군, 기존의 타사제품을 투여한 양성대조군, 블렌시아 살미언티 추출물을 제외한 음료 베이스 투여군과 비교함으로써, 블렌시아 살미언티 추출물이 혈액 중 알코올 농도와 아세트알데히드의 농도를 감소시키는 한편 알코올 탈수소효소 활성에는 영향을 미치지 않음을 확인함으로써 달성되었다.
An object of the present invention as described above is to prepare a blancia salmity extract, the effect of the blood alcohol concentration, alcohol dehydrogenase (ADH) and acetaldehyde (ALDH) concentration in the untreated normal group, ethanol control, conventional Compared to the beverage-based administration group except the positive control group and the blancia salmity extract, which were administered other company's products, the blancia salmity extract reduced the alcohol concentration and acetaldehyde concentration in the blood and affected the alcohol dehydrogenase activity. Achieved by confirming that no
본 발명은 블렌시아 살미언티(Bulnesia sarmienti) 추출물을 유효성분으로 함유하는 숙취해소용 약제학 조성물을 제공한다.The present invention provides a pharmaceutical composition for releasing hangovers containing Bulnesia sarmienti extract as an active ingredient.
본 발명에 있어서, 상기 블렌시아 살미언티 추출물이 혈액 중 알코올 농도를 감소시키는 것을 특징으로 한다.In the present invention, the blancia salmity extract is characterized by reducing the alcohol concentration in the blood.
본 발명에 있어서, 상기 블렌시아 살미언티 추출물이 혈액 중 아세트알데히드 농도를 감소시키는 것을 특징으로 한다.In the present invention, the blancia salmity extract is characterized by reducing the acetaldehyde concentration in the blood.
또한 본 발명은 블렌시아 살미언티(Bulnesia sarmienti) 추출물을 유효성분으로 함유하는 숙취해소용 식품 조성물을 제공한다.In another aspect, the present invention provides a hangover relief food composition containing Bulnesia sarmienti extract as an active ingredient.
본 발명에 있어서, "유효성분"이라 함은 내재된 약리작용에 의해 그 의약품의 효능, 효과가 직접 또는 간접적으로 발현한다고 기대되는 물질 또는 물질군(약리학적 활성성분등이 밝혀지지 않은 생약 등을 포함한다)으로서 주성분을 포함하는 것을 의미한다.In the present invention, the term "active ingredient" refers to a substance or a group of substances (a pharmacologically active ingredient or the like, which is expected to express the efficacy or effect of the drug directly or indirectly by intrinsic pharmacological action). It means containing a main component).
본 발명의 추출물을 포함하는 약제학적 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.Pharmaceutical compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명에 따른른 블렌시아 살미언티 추출물을 포함하는 약제학적 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. Pharmaceutical compositions comprising the blended blancia salmity extract according to the present invention, powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc. And in the form of sterile injectable solutions.
본 발명에 따른 블렌시아 살미언티 추출물을 포함하는 약제학적 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출액에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calciumcarbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Carriers, excipients and diluents that may be included in the pharmaceutical composition comprising the blancia salmity extract according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia Rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil Can be. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations include at least one excipient such as starch, calcium carbonate, sucrose in the extract. Or lactose, gelatin, or the like is mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명에 따른 블렌시아 살미언티 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.001 내지 100 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Preferred dosages of the blancia salmimony extract according to the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명에 따른 블렌시아 살미언티 추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식이 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내(intracerebroventricular) 주사에 의해 투여될 수 있다. The blancia salmity extract according to the present invention can be administered to various mammals such as mice, mice, livestock, humans, and the like. All modes of administration can be envisaged, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
또한, 본 발명에 따른 블렌시아 살미언티 추출물은 숙취해소 개선 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 블렌시아 살미언티 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류, 분말, 과립, 정제, 캡슐 또는 음료 등이 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다.In addition, the blancia salmity extract according to the present invention may be added to food or beverage for the purpose of improving hangover relief. Examples of the food to which the blancia salmity extract can be added include various foods, beverages, gums, teas, vitamin complexes, health functional foods, powders, granules, tablets, capsules or beverages. At this time, the amount of the extract in the food or beverage can be added in 0.01 to 15% by weight of the total food weight, the health beverage composition is added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml Can be.
본 발명의 식품 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에는 다른 성분에 는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다. The food composition of the present invention is not particularly limited to other ingredients except for containing the extract as an essential ingredient in the indicated proportions, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 블렌시아 살미언티 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 추출물은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 추출물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above, the blancia salmity extract of the present invention is a flavor, such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and its Salts, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. In addition, the extract of the present invention may contain natural fruit juice and fruit flesh for the production of fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
본 발명에 따른 블렌시아 살미언티 추출물은 혈액 중 알코올 농도와 아세트알데히드의 농도를 감소시키는 한편 알코올 탈수소효소 활성에는 영향을 미치지 않아 숙취해소에 매우 우수한 효과를 나타낸다.
Blencia salmity extract according to the present invention reduces the concentration of alcohol and acetaldehyde in the blood and does not affect the alcohol dehydrogenase activity shows a very excellent effect on hangover.
도 1은 본 발명에 따른 실험 방법을 개략적으로 나타낸 도이다.
도 2는 실험동물에서 에탄올 투여 후 아세트알데히드 농도 변화를 나타낸 그래프이다.1 is a view schematically showing an experimental method according to the present invention.
Figure 2 is a graph showing the change of acetaldehyde concentration after administration of ethanol in experimental animals.
이하에서 본 발명의 바람직한 실시형태를 실시예를 참고로 보다 구체적으로 설명한다. 하지만 본 발명의 범위가 이러한 실시예에 한정되는 것은 아니다.
Hereinafter, preferred embodiments of the present invention will be described in more detail with reference to Examples. However, the scope of the present invention is not limited to these examples.
실시예 1 : 블렌시아 살미언티 음료의 제조Example 1 Preparation of a Blensia Salmonti Beverage
블렌시아 살미언티는 (주)럭키약품으로부터 건조된 가루형태로 공급받아 9 mg/mL(0.9%, w/v) 비율로 증류수를 가하여 압력식 추출기로 100℃에서 3시간 동안 추출 후 여과지(Whatman, No.2)로 여과하였다. 여과한 추출액을 농축한 다음 음료 베이스와 혼합하여 음료로 제조하고, 다음 실험에 사용하였다.
Blensia Salmity is supplied as a dry powder from Lucky Chemicals Co., Ltd., and distilled water is added at 9 mg / mL (0.9%, w / v). Whatman, No. 2). The filtered extract was concentrated and then mixed with the beverage base to prepare a beverage, which was used in the next experiment.
실험예Experimental Example
실험동물은 생후 7주령 수컷 흰쥐(Sprague Dawley)를 구입하여 고형사료와 물을 공급하면서 일주일간 적응시킨 후 평균체중 281±10.3 g인 것을 사용한다. 음수는 자외선으로 멸균된 물과 사료를 자유롭게 섭취시켰다. 실험기간 동안 사육환경은 온도 20-22℃, 상대습도 50±1%, 환기횟수 10~15회/hr, 명암주기 12시간 간격, 조도 150~300 lux로 유지하였다. The experimental animals purchased 7 week old male rats (Sprague Dawley) were used for 1 week while feeding solid food and water, and then used the average weight of 281 ± 10.3 g. Negative water was freely consumed by UV sterilized water and feed. During the experimental period, the breeding environment was maintained at a temperature of 20-22 ° C, a relative humidity of 50 ± 1%, a ventilation frequency of 10-15 times / hr, a light / dark cycle of 12 hours, and an illuminance of 150-300 lux.
상기 흰쥐에 급성 알코올중독을 유발하기 위하여 에탄올을 체중 kg당 4g수준으로 1회 경구투여 하였다. 하기 표 1에서와 같이, 실험군은 정상군(NO군), 에탄올 대조군(CO군), 기존의 타사제품을 투여한 양성대조군(PC군), 블렌시아 살미언티 추출물 함유한 음료 투여군(BSP군), 블렌시아 살미언티 추출물을 제외한 음료 베이스 투여군(NBS군) 으로 총 5그룹 이며, 각 군당 7마리씩 총 35마리를 실험에 사용하였다. To induce acute alcoholism in the rat, ethanol was orally administered once at a level of 4 g / kg body weight. As shown in Table 1, the experimental group is a normal group (NO group), ethanol control group (CO group), the positive control group (PC group) administered the existing third-party products, beverage administration group containing the Blensia Salmonity extract (BSP group) ), Beverage base administration group (NBS group), except for the Blensia Salmonti extract, was a total of five groups, and a total of 35 animals, 7 of each group, were used for the experiment.
<표 1>TABLE 1
에탄올 대조군은 블렌시아 살미언티 추출물 함유 음료 대신 동일한 용량의 증류수를 10 mL/kg씩 경구 투여하였다. 최종 투여가 완료된 후 시간경과에 따른 혈중 알코올 농도를 측정하기 위해 가벼운 에테르 마취상태에서 경시적(60, 120, 180분)으로 안와정맥총에서 채혈하며, 채혈한 혈액은 응고시킨 후 600 x g에서 15분간 원심분리로 혈청을 분리하여 알코올 농도측정에 사용하였다.
The ethanol control group was orally administered 10 mL / kg of the same dose of distilled water instead of the beverage containing the blendia salmity extract. After completion of the final dose, blood was collected from the orbital vein over time (60, 120, 180 minutes) under light ether anesthesia to measure blood alcohol concentration over time, and the collected blood was coagulated for 15 minutes at 600 xg. Serum was separated by centrifugation and used for alcohol concentration measurement.
실험예 1 : 혈액 중 알코올 농도, 알콜탈수소효소(ADH) 및 아세트알데히드(ALDH) 농도 측정Experimental Example 1 Measurement of Alcohol Concentration, Alcohol Dehydrogenase (ADH) and Acetaldehyde (ALDH) Concentration in Blood
혈액 중 알코올 농도는 에탄올 분석 알코올 키트(Roche-BM., Switzerland)를 이용하여 측정하였고 원리는 다음과 같다.Alcohol concentration in blood was measured using the ethanol assay alcohol kit (Roche-BM., Switzerland) and the principle is as follows.
에탄올 + NAD+--------------아세트알데히드 + NADH + H+ Ethanol + NAD + -------------- Acetaldehyde + NADH + H +
NADH의 형성은 378nm에서 흡광도 증가로 정량할 수 있다. 1,3-디아미노-2-하이드록시프로판이 알데하이드를 포획하는 시약이며, 효과적인 완층액으로 작용한다.Formation of NADH can be quantified by increased absorbance at 378 nm. 1,3-diamino-2-hydroxypropane is a reagent that captures aldehydes and acts as an effective slow effluent.
혈액중 알콜 탈수소효소(ADH)농도는 바소프레신 다이렉트(Vasopressin Direct)(Buhlmann, Switzerland)를 이용하여 측정하였고 원리는 다음과 같다.Blood alcohol dehydrogenase (ADH) concentration was measured using Vasopressin Direct (Buhlmann, Switzerland).
면역반응성 바소프레신(Immunoreactive vasopressin)은 이중항체법의 RIA 검사로 글릭크 등(Glick & Kagan)의 방법을 변형한 것으로 먼저 표준물질, 검체를 24시간 동안 항-바소프레신 항체와 반응시킨 후, 그 결합물질에 다시 125I-바소프레신을 넣고 24시간 반응시켰다. 이 결합물질에 고상 2차 항체를 첨가하여 혼합하면 항체-결합 분획이 침전되는데 이를 계수하였다.Immunoreactive vasopressin is a variant of the Glick & Kagan method of dual antibody RIA testing, first reacting a standard, sample with an anti-vasopressin antibody for 24 hours, and then the binding material. To 125 I- vasopressin was added again and reacted for 24 hours. When the solid secondary antibody was added and mixed with the binding material, the antibody-binding fraction was precipitated and counted.
혈액 중 아세트알데히드 농도 측정은 아세트알데히드 Cat. no. 668613)(BOEHRINGER MANNHEIM, Germany)를 사용하여 측정하였고 검사 원리는 다음과 같다. Measurement of acetaldehyde concentration in the blood is determined by acetaldehyde Cat. no. 668613) (BOEHRINGER MANNHEIM, Germany) and the test principle is as follows.
Al-DH Al-DH
아세트알데히드 +NAD++H2O-----아세트산 +NADH+H+
Acetaldehyde + NAD + + H 2 O ----- Acetic acid + NADH + H +
아세트알데히드는 NAD와 물, Al-DH 효소에 의해 NADH와 H로 가수분해되고, 아세트산으로 산화된다. 검체 중에 NADH화된 아세트알데히드 양을 334,340 또는 365 nm 에서 측정하였다.Acetaldehyde is hydrolyzed to NADH and H by NAD, water, and Al-DH enzymes and oxidized to acetic acid. The amount of NADHylated acetaldehyde in the sample was measured at 334,340 or 365 nm.
모든 실험결과는 평균±표준오차로 나타내었으며, 각 그룹 및 평균간 통계적 유의성은 SPSS 10.0 (SPSS Inc, IL, USA)를 이용하여 일방향 ANOVA 분석 후 p<0.05 수준에서 던컨 다중 범위 시험(Duncan's multiple test)에 의해 검정하였다.
All experimental results were expressed as mean ± standard error, and statistical significance between each group and mean was Duncan's multiple test at p <0.05 after one-way ANOVA analysis using SPSS 10.0 (SPSS Inc, IL, USA). Assay).
알코올 투여 30분 후에 블렌시아 살미언티 추출물 함유 음료를 경구적으로 섭취시켰을 때 시간적으로 나타내는 혈액 중 알코올의 농도 변화는 표 2과 같다. Table 2 shows changes in alcohol concentrations in blood when orally ingested with a blend of blancia salmonti extract 30 minutes after alcohol administration.
<표 2>TABLE 2
실험동물에서 에탄올 투여 후 혈 중 알코올 농도Blood Alcohol Concentration After Ethanol Administration in Experimental Animals
알코올을 투여한 모든 그룹에서 시간에 경과함에 따라 정상군(NO군)에 비하여 체내 혈 중 알코올 함량이 나타났다. 알코올 대조군(CO군)은 실험시간(60분~180분)내 체내 알코올 함량이 줄여들지 않고 유지된 상태를 보였으나, 타사 제품을 투여한 양성대조군(PC군), 블렌시아 살미언티 추출물 함유 음료군(BSP) 및 블렌시아 살미언티 추추물을 제외한 음료 베이스 투여군(NBS)군은 알코올 투여 후 180분 후 44.27~52.32% 낮은 체내 알코올 함량 수치를 보였다. The blood alcohol content in the body was higher than the normal group (NO group) over time in all groups administered with alcohol. The alcohol control group (CO group) showed a state of maintaining the alcohol content in the body within the experiment time (60 minutes to 180 minutes) without reduction, but it contained the positive control group (PC group) and the blancia salmity extract administered with other products. The beverage base-administered group (NBS) group, except for the beverage group (BSP) and the blancia salmonium extract, showed 44.27-52.32% lower alcohol content after 180 minutes of alcohol administration.
특히, 블렌시아 살미언티 추출물 함유 음료군(BSP)의 알코올 함량은 70.33±2.35 mg/dl plasma로 타사 제품을 투여한 양성대조군(PC군)의 알코올 함량 76.83±3.39 mg/dl plasma 및 블렌시아 살미언티 추추물을 제외한 음료 베이스 투여군(NBS)의 알코올 함량 82.20±5.73 mg/dl plasma 보다도 4.41~8.05% 낮은 수치를 보여 숙취 개선에 가장 좋은 것으로 분석 되어졌다. In particular, the alcohol content of the blend group (BSP) containing blancia salmity extract was 70.33 ± 2.35 mg / dl plasma, and the alcohol content of the positive control group (PC group) was 76.83 ± 3.39 mg / dl plasma and blancia It was analyzed that it is the best for improving hangover by showing 4.41 ~ 8.05% lower than alcohol content of 82.20 ± 5.73 mg / dl plasma in beverage base administration group (NBS) except Salmonity extract.
알코올 투여 30분 후에 블렌시아 살미언티 추출물 함유 음료를 경구적으로 섭취시켰을 때 체내 알코올을 분해하는 효소인 알코올 탈수소효소(ADH)의 활성을 시간적으로 살펴 본 결과는 표 3과 같다. After 30 minutes of alcohol administration, when the oral intake of the blancia salmonti extract-containing beverage was examined in time, the activity of alcohol dehydrogenase (ADH), an enzyme that decomposes the alcohol in the body, is shown in Table 3.
<표 3>TABLE 3
실험동물에서 에탄올 투여 후 알코올 탈수소효소 활성Alcohol Dehydrogenase Activity After Ethanol Administration in Experimental Animals
알코올을 투여하지 않은 정상군(NO군)의 효소 활성은 큰 변화가 없었으나, 알코올만 투여한 알코올 대조군(CO군)의 효소 활성이 알코올 투여 후 급격히 활성이 떨어짐이 관찰되었다. There was no significant change in the enzyme activity of the normal group (no group) without alcohol, but the enzyme activity of the alcohol control group (co group) with alcohol only decreased rapidly after alcohol administration.
이에 반해 알코올 투여 후 샘플을 처리한 실험군인 타사 제품을 투여한 양성대조군(PC군), 블렌시아 살미언티 추출물 함유 음료군(BSP) 및 블렌시아 살미언티 추추물을 제외한 음료 베이스 투여군(NBS)군은 알코올 투여 후에도 효소 활성에 큰 변화가 없는 것으로 나타내었다. 그 중 특히 블렌시아 살미언티 추출물 함유 음료군(BSP군)의 효소 활성이 112.75±5.23 pg/m plasma로 가장 높게 나타났으며 이는 대조군의 87.90±5.40 pg/m plasma에 비해 28.27% 가량 높은 수치이다.
In contrast, the positive control group (PC group), the blend group containing the Blensia Salmonity extract (BSP) and the blending base of the beverage base except the Blensia Salmonity extract (NBS), which received the third-party product, the experimental group that processed the sample after alcohol administration (NBS). ) Showed no significant change in enzyme activity even after alcohol administration. Among them, the enzyme activity of the drink group (BSP group) containing the blancia salmity extract was the highest with 112.75 ± 5.23 pg / m plasma, which is 28.27% higher than the 87.90 ± 5.40 pg / m plasma of the control group. to be.
알코올 투여 후 3시간 후 혈액 중 아세트알데히드 농도를 측정한 결과를 도 2와 같다. 숙취 증상을 야기 시키는 것으로 알려진 아세트알데히드의 양은 알코올 대사를 빠르게 진행시켜 그 농도를 낮출 수 있는데, 이로 인해 알코올로 야기 되는 숙취를 경감시킬 수 있다.After 3 hours after alcohol administration, the result of measuring acetaldehyde concentration in blood is shown in FIG. 2. The amount of acetaldehyde known to cause hangover symptoms can accelerate alcohol metabolism and lower its concentration, thereby reducing the hangover caused by alcohol.
알코올을 투여한 모든 그룹에서 아세트알데히드의 농도가 정상군(NO군)에 비하여 각각 알코올 대조군(CO군)은 0.52±0.03 mg/dl plasma, 양성대조군(PC군)은 0.46±0.04 mg/dl plasma, 블렌시아 살미언티 추출물 함유 음료군(BSP)은 0.32±0.01 mg/dl plasma, 블렌시아 살미언티 추추물을 제외한 음료 베이스 투여군(NBS)은0.38±0.02 mg/dl plasma로서 농도가 높았다. 하지만 알코올을 투여하였지만 숙취개선 샘플 처리에 의하여 PC군, BSP군, NBS군의 아세트알데히드의 농도는 낮아졌으며, 그 중 알코올 대조군 CO군의 아세트알데히드 농도(100%)에 비하여 BSP군이 61.5%로 가장 낮게 나타내어 숙취개선 효과가 가장 뛰어 난 것으로 나타났다. Acetaldehyde concentration was 0.52 ± 0.03 mg / dl plasma in alcohol control group (CO group) and 0.46 ± 0.04 mg / dl plasma in positive control group (PC group) compared to normal group (NO group). The beverage group (BSP) containing blancia salmity extract was 0.32 ± 0.01 mg / dl plasma, and the beverage base administration group (NBS) except the blancia salmian extract was 0.38 ± 0.02 mg / dl plasma. However, although alcohol was administered, acetaldehyde concentrations of PC, BSP and NBS groups were lowered by hangover improvement sample treatment. Among them, BSP group was 61.5% compared to acetaldehyde concentration (100%) of alcohol control CO group. The lowest level was found to be the best hangover improvement effect.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100005218A KR101157096B1 (en) | 2010-01-20 | 2010-01-20 | Composition for relieving hangover containing Bulnesia sarmienti extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100005218A KR101157096B1 (en) | 2010-01-20 | 2010-01-20 | Composition for relieving hangover containing Bulnesia sarmienti extracts |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110085433A true KR20110085433A (en) | 2011-07-27 |
KR101157096B1 KR101157096B1 (en) | 2012-06-22 |
Family
ID=44922228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100005218A KR101157096B1 (en) | 2010-01-20 | 2010-01-20 | Composition for relieving hangover containing Bulnesia sarmienti extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101157096B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111295094A (en) | 2017-10-09 | 2020-06-16 | 泰尔茂比司特生物技术有限公司 | Freeze-drying container and method for using freeze-drying container |
CA3130668A1 (en) | 2019-03-14 | 2020-12-03 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100890945B1 (en) * | 2007-08-13 | 2009-03-27 | 재단법인 대구테크노파크 | Beverage comprising Bulnesia sarmienti extract and a preparation method thereof |
-
2010
- 2010-01-20 KR KR1020100005218A patent/KR101157096B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR101157096B1 (en) | 2012-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8496977B2 (en) | Natural extract from whole banana fruit (Musa Spp) | |
JP5937596B2 (en) | Urushi extract with increased content of active flavonoid compound and method for producing the same | |
US20100105766A1 (en) | Composition for inhibition or prevention of bone density reduction | |
KR101974442B1 (en) | Agent for improvement of catechin bioavailability comprising cyclodextrin | |
KR102064651B1 (en) | Composition for preventing or improving diabetes mellitus comprising momrdica charantia (l.) extract, chrysanthemum zawadskii var. latilobum and paeonia lactiflora extract as an effective ingredient | |
JP4422685B2 (en) | Use of pinitol or cayloisitol for liver protection | |
KR101157096B1 (en) | Composition for relieving hangover containing Bulnesia sarmienti extracts | |
KR20140137289A (en) | Composition comprising an extract of Alpinia officinarum Hance for preventing and treating hangover or liver disease | |
KR100527109B1 (en) | Pharmaceutical composition comprising the extract of Allium tuberosum ROTTER for the prevention and treatment of gout. | |
KR100473530B1 (en) | Composition containing an extract of sopungsungi-won crude drug complex for preventing and treating diabetes mellitus | |
KR102045847B1 (en) | Kyung-ok-go having high acceptability and anti-diabetes activity adding the silk of zea mays and pumpkin | |
KR101808808B1 (en) | Compositions for preventing and treating diabetes or diabetic complications comprising extracts of Acer tegmentosum Maximowoca and Magnolia officinalis Rehd. et Wils. | |
KR100895500B1 (en) | Composition for the prevention and treatment of fatty liver diseases containing honokiol as an active ingredient | |
KR100473531B1 (en) | Composition containing an extract of truncated sopungsungi-won crude drug complex for preventing and treating diabetes | |
KR100526628B1 (en) | Composition comprising the extract of Morus alba L having monoamine oxidase-inhibiting activity | |
KR100468073B1 (en) | Composition comprising from an extract of Salicornia herbacea or isorhamnetin-3-O-β-D-glucoside isolated therefrom | |
KR100535322B1 (en) | Pharmaceutical composition comprising the extract of Allium tuberosum Rottler for treating or preventing diabetes mellitus | |
KR100561251B1 (en) | Composition comprising the extract of Glycine max having monoamine oxidase-inhibiting activity | |
KR101991746B1 (en) | Agent for improvement of cathechin bioavailability | |
KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
EP2052728B1 (en) | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia | |
KR100562525B1 (en) | Composition containing a polysaccharide fraction isolated from cordyceps militaris for preventing and treating diabetes mellitus | |
KR100991398B1 (en) | Compositions for anti-inflammation containing Desmarestia viridis extracts as an active ingredient | |
WO2007004570A1 (en) | Composition having physical endurance improving effect and/or anti-fatigue effect | |
KR101886802B1 (en) | Agent for improvement of cathechin bioavailability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |